scout
|Articles|March 23, 2009

Oncology NEWS International

  • Oncology NEWS International Vol 18 No 3
  • Volume 18
  • Issue 3

Oncolytics kicks off reovirus trial

Oncolytics will start a U.S. phase II trial on Reolysin (reovirus serotype 3) and chemotherapy for NSCLC. Oncolytics said that Reolysin, in combination with certain chemotherapeutics, results in more efficient and synergistic anti-cancer activity than when each agent is used on its own.

Oncolytics will start a U.S. phase II trial on Reolysin (reovirus serotype 3) and chemotherapy for NSCLC. Oncolytics said that Reolysin, in combination with certain chemotherapeutics, results in more efficient and synergistic anti-cancer activity than when each agent is used on its own.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.


Latest CME